Consolidated Financial Result Briefing
for nine months ended December 31, 2023

CYBERDYNE, Inc.
February 14, 2024

Consolidated financial results (IFRS)
Year-on-year comparison for the nine months ended December 31, 2023
Revenue: 3,219M (+36% YoY)
Operating profit: -1,603M*3 (without temp expenses on Q2 -943M)
Profit before tax: -566M*3 (without temp expenses on Q2 94M)☆☆

Revenue(Gross profit)

Operating profit

Profit before tax

Profit attributable toowner of the parent

FY2022(Q1 to Q3)

FY2023(Q1 to Q3)+/-+/-%

2,374(1,316)

3,219(1,742)+845 *1(+426)+35.6％-749-1,603112-566*2*3*4*5-951*1 Increase of revenue (845M) (YoY)
Rental +118M (Increase of rental outside Japan)
Treatment service +323M (from U.S. Rise Group)
New business +404M (Acquisition of German mobility company)*２ SG&A (645M) (YoY)
SG&A of two acquired foreign subsidiaries +601M

-854

ー

*３ Other expenses

-678

ー

*４ Investment securities 892M (Net) *735M in the previous quarter

Temp expenses from impairment loss of goodwill in Q2 +660M

Financial income/expenses 191M, Gains related to CEJ Fund 701M

*668(+32.4%)(Unit: Millions of yen)

-1,020ー*５ Other Foreign exchange gain 96M (+29M YoY)

*６ Income taxes 506M (+400M YoY)☆

EBITDA

-517

-583

-65

ー

Tax effect on gain on valuation 508M (+357M YoY)

⭐EBITDA = Operating profit＋Depreciation and amortization ± Other income and expense⭐⭐ Due to the revision of cost of sales for treatment services, a part of other SG&A expenses in FY2022Q3 was transferred to cost of sales.

2Consolidated financial results (IFRS)
Performance trends【Q3 Results】Revenue +34% (QoQ)
Consolidated statementof profit or loss

Revenue

FY2022☆

Q3Q1Q2(Unit: Millions of yen)

FY2023Q3

前四半期比較(QoQ)

累計

増減額

増減率

前年同四半期比較(YoY)
増減額

増減率

831

1,045

1,058

1,115

3,219

+57+5.4%+284+34.1%

440

480

480

517

1,477

+38+7.9%+77+17.5%

391

566

579

598

1,742+19+3.3%+206+52.8%

R&D expenses

161

174

180

163

517

-17-9.2%+2+1.2%Other SG&A
Other income/expenses

551

766

757

771

2,293+14+1.9%+220+40.0%

1367-651

49-535+700-+36+273.7%

Operating profit
Finance income/expenseOther-307-308-1,008-287-1,603

+722

-+21-

10363

-12-106

245

-94-

-116

-

36712

74

6792

-67

-91.3%-29-82.0%

Profit before tax

-261

767

-947

-386

-566

+561

--125

-

Profit attributable toowner of the parent

-200

330

-933

-349

-951

+584

-

-149

-

EBITDA-216-212-194-177-583+17-+39-

Cost of sales
Gross profit

With out the temporary expenses (660M) -348M☆Transferred a portion of other SG&A expenses in FY2022 Q3 to the cost of sales due to a review of the cost of sales for treatment services

3

Consolidated financial results: Revenue/Operating profit (Margin)
Operating profit from rental of products 597M (Operating profit margin 46%)
FY2022Q1 to Q3

FY2023Q1 to Q3+/-YoY

Revenue

1,177+118+10%

Operating profit(Margin)

498(42%)

1,294☆

Revenue916+323+35%

Operating profit(Margin)-174(-19%)

1,239

☆

281685+404+144%☆

Rental of productTreatment service
New businessexpansion☆ ☆ RD expenses andHead office expenses

Consolidated total(IFRS)☆

(Unit: Millions of yen)

Revenue

597
(46%)

-351
(-28%)+99-177

Operating profit(Margin)-115(-19%)-185(-27%)

Adjusted amount-958-1,664-706

Revenue

2,374

3,219+845

Operating profit(Margin)-749(-32%)

Operating income by business segment is the amount of profit or loss, which is revenue minus operating expenses, for each business.

☆☆ RD expenses and head office expenses, are adjustment amount of R&D expenses, head office administrative expenses, other income and expenses, etc.

-1,603(-50%)-70-854+20%--+36%-• Rental of product: Rental income from the Group’s product (include income from sold products)• Treatment service: Income from treatment at the Group’s rehabilitation facilities (including Robocare)• New business expansion: Revenue from new business area of the Group (subsidiary company in mobility and sleep apps)

Without temporary expense (660M) in Q2, -1,004M
4

Changes of rental revenue by each products
Overseas product rental sales increased by 174M YoY (+39%)
Product classification
HAL Lower Limb Type(Medical)
For Hospitals(improving function)

Care support
and well-being

Japan

Outside Japan

Total(Unit: Millions of yen)247

397+53％644

Top row：FY2023 Q1 to Q3

(246)

(259)

(505)

122

-

122

HAL Single Joint Type

68

77

144

HAL Lumbar Type

86

74

160

HAL Lumbar Type

32-

32

Mobile robot (CL02 etc.)

83

-

83

Other3970

110

Total

676

618 +39％

1,294

HAL Lower Limb Type(Non-medical)

Labor Support

(131)

(88)

(115)
(52)
(54)
(47)

(732)

(62)
(82)

(42)

(444)

(Bottom row：FY2022 Q1 to Q3)

(131)

(149)
(197)
(52)
(54)
(89)

(1,177)

5

Consolidated financial results (IFRS)
by geographical region
Siginificant increase of oversea sale +912M (52% to 67% of total revenue)

Japan 33%

¥1,137M

Americas 33%¥1,065M

Americas 35%

¥790M

Japan

APAC 11%48%¥1,133M

EMEA 8%

¥193M

¥346M

EMEA 21%

¥257M

¥670M

APAC 11%
FY2022 Q1 to Q3

FY2023 Q1 to Q3

Americas: North, Central and South America
EMEA : Europe, the Middle East and Africa
APAC : Asia-Pacific * Revenue from Japan is stated separately
6Ref) Consolidated financial results (IFRS)
by geographical regions and type of transaction
Oversea revenue increases in each type of transaction(Unit: Millions of yen)

FY2023 Q1-Q2(FY2022 Q1-Q2)

Rental of productTreatment service

New business

Total

Japan

Americas676 -8％(732)107-10％281+0％(120)+9％(42)

1,091+46％
(747)

(281)

1,065 -6％

(1,133)46

1,137 +44％(790)

EMEA

APAC

Total

226 +56％

346 +35％

1,294 +10％(145)

40-17％(49)404(-)

670 +246％(193)(257)

346 +35％(257)(1,177)

1,239 +35％
(916)

685 +144％(281)

3,219 +36％

(2,374)7

Disclaimer

This presentation contains forward-looking statements concerning
CYBERDYNE, Inc. and its Group’s future plans, strategies and performance.
Forward-looking statements contained in this presentation are based on
information currently available and on certain assumption redeemed rational at
the time of creation of this presentation. As such, due to various risks anduncertainties, the statements and assumption does not guarantee future
performance, may be considered differently from alternative perspectives andmay differ from the actual result.
Further, this presentation contains statements and information regarding
corporate entities other than those belonging to the CYBERDYNE group, whichhave been complied from various publicly- available sources. CYBERDYNE
does not verify nor guarantees accuracy and appropriateness of thoseinformation.

8